ABSTRACT
Objective: To investigate the clinicopathological and
immunohistochemical features of triple-negative breast cancer. Methods: The clinicopathological and immunohistochemical
data (Ki-67, CK5/6, EGFR, E-Ca, SAM, P53, P63, FAS) of 199 female patients who were treated for breast cancer in thyroid and breast surgery of Xiaogan
Central Hospital from January 2015 to December 2016 was retrospectively analyzed by using spss22.0 statistical software and
chi-square analysis. Results: Triple-negative breast cancer (replaced
by TNBC below) and non-triple negative breast cancer (replaced
by non TNBC below) in age, tumor size, lymph node metastasis, SAM, P53, P63 and
FAS have no statistical difference (P > 0.05, see Table 1), while in WHO grade of invasive ductal carcinoma, KI-67, CK5/6, EGFR, E-Ca
they have statistical differences (P < 0.05, see Table 1). The invasive ductal carcinoma WHO grade of TNBC is higher than that of
non TNBC. It’s positive rate of Ki-67, CK5/6, EGFR (96.67%,
58.33%, 72.22%) and negative rate of E-Ca (68.18%) are higher than those of non
TNBC (75.74%, 29.03%, 18.92%, 30.38%) (P < 0.05, see Table 1). Conclusions: The invasive ductal carcinoma WHO grade of TNBC is
higher than that of non TNBC, while it’s
Ki-67, CK5/6, EGFR positive rate and the negative rate of E-Ca are
significantly higher than those of non TNBC. The
immunohistochemical index above is expected to become potential targets for the
treatment of TNBC.